Trial Profile

CFTR Biomarker Studie Bei Patient Innen Mit Mukoviszidose Und CFTR-Modulatortherapie

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor (Primary) ; Ivacaftor/lumacaftor (Primary) ; Ivacaftor/tezacaftor (Primary)
Indications Cystic fibrosis
Focus Biomarker; Therapeutic Use
Acronyms Modulate-CF

Most Recent Events

24 Feb 2026 Planned number of patients changed from 200 to 500.
01 Mar 2024 Planned number of patients changed from 90 to 200.
01 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com